Spanish RNAi drugs shop Sylentis has completed non-human primate studies of a topical siRNA-based treatment for glaucoma and aims to begin testing the drug in humans before the end of the year, RNAi News has learned.

The company will perform initial clinical testing on its own in Spain, though it expects to later test the drug in other countries, including the US, Natalia Wright, Sylentis' head of intellectual property, told RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.